Literature DB >> 19563910

PPARgamma activation induces autophagy in breast cancer cells.

Jie Zhou1, Wei Zhang, Bing Liang, Mathew C Casimiro, Diana Whitaker-Menezes, Min Wang, Michael P Lisanti, Susan Lanza-Jacoby, Richard G Pestell, Chenguang Wang.   

Abstract

It has been previously shown that PPAR gamma ligands induce apoptotic cell death in a variety of cancer cells. Given the evidence that these ligands have a receptor-independent function, we further examined the specific role of PPAR gamma activation in this biological process. Surprisingly, we failed to demonstrate that MDA-MB-231 breast cancer cells undergo apoptosis when treated with sub-saturation doses of troglitazone and rosiglitazone, which are synthetic PPAR gamma ligands. Acridine orange (AO) staining showed acidic vesicular formation within ligand-treated cells, indicative of autophagic activity. This was confirmed by autophagosome formation as indicated by redistribution of LC3, an autophagy-specific protein, and the appearance of double-membrane autophagic vacuoles by electron microscopy following exposure to ligand. To determine the mechanism by which PPAR gamma induces autophagy, we transduced primary mammary epithelial cells with a constitutively active mutant of PPAR gamma and screened gene expression associated with PPAR gamma activation by genome-wide array analysis. HIF1 alpha and BNIP3 were among 42 genes up-regulated by active PPAR gamma. Activation of PPAR gamma induced HIF1 alpha and BNIP3 protein and mRNA abundance. HIF1 alpha knockdown by shRNA abolished the autophagosome formation induced by PPAR gamma activation. In summary, our data shows a specific induction of autophagy by PPAR gamma activation in breast cancer cells providing an understanding of distinct roles of PPAR gamma in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19563910      PMCID: PMC2753745          DOI: 10.1016/j.biocel.2009.06.007

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  57 in total

1.  15-Deoxy-delta12,14-prostaglandin J2-induced apoptosis does not require PPARgamma in breast cancer cells.

Authors:  Carl E Clay; Arta Monjazeb; Jacqueline Thorburn; Floyd H Chilton; Kevin P High
Journal:  J Lipid Res       Date:  2002-11       Impact factor: 5.922

2.  Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression.

Authors:  Songtao Yu; Kimihiko Matsusue; Papreddy Kashireddy; Wen-Qing Cao; Vaishalee Yeldandi; Anjana V Yeldandi; M Sambasiva Rao; Frank J Gonzalez; Janardan K Reddy
Journal:  J Biol Chem       Date:  2002-10-24       Impact factor: 5.157

3.  Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines.

Authors:  Kaname Yoshizawa; Daniel P Cioca; Shigeyuki Kawa; Eiji Tanaka; Kendo Kiyosawa
Journal:  Cancer       Date:  2002-11-15       Impact factor: 6.860

4.  Peroxisome proliferator-activated receptor- gamma expression in human malignant and normal brain, breast and prostate-derived cells.

Authors:  J O Nwankwo; M E Robbins
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2001 Apr-May       Impact factor: 4.006

5.  A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis.

Authors:  N Suh; Y Wang; C R Williams; R Risingsong; T Gilmer; T M Willson; M B Sporn
Journal:  Cancer Res       Date:  1999-11-15       Impact factor: 12.701

6.  PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation.

Authors:  A Chawla; Y Barak; L Nagy; D Liao; P Tontonoz; R M Evans
Journal:  Nat Med       Date:  2001-01       Impact factor: 53.440

7.  Therapeutic treatment of DMBA-induced mammary tumors with PPAR ligands.

Authors:  G M Pighetti; W Novosad; C Nicholson; D C Hitt; C Hansens; A B Hollingsworth; M L Lerner; D Brackett; S A Lightfoot; J M Gimble
Journal:  Anticancer Res       Date:  2001 Mar-Apr       Impact factor: 2.480

8.  A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions.

Authors:  R G Mehta; E Williamson; M K Patel; H P Koeffler
Journal:  J Natl Cancer Inst       Date:  2000-03-01       Impact factor: 13.506

9.  Inhibition of cellular proliferation through IkappaB kinase-independent and peroxisome proliferator-activated receptor gamma-dependent repression of cyclin D1.

Authors:  C Wang; M Fu; M D'Amico; C Albanese; J N Zhou; M Brownlee; M P Lisanti; V K Chatterjee; M A Lazar; R G Pestell
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

10.  Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth.

Authors:  Maria Luisa Martelli; Rodolfo Iuliano; Ilaria Le Pera; Irene Sama'; Carmen Monaco; Simona Cammarota; Todd Kroll; Lorenzo Chiariotti; Massimo Santoro; Alfredo Fusco
Journal:  J Clin Endocrinol Metab       Date:  2002-10       Impact factor: 5.958

View more
  50 in total

1.  MK886 inhibits the pioglitazone-induced anti-invasion of MDA-MB-231 cells is associated with PPARα/γ, FGF4 and 5LOX.

Authors:  Kalpanah Nadarajan; Prabha Balaram; Boon Yin Khoo
Journal:  Cytotechnology       Date:  2016-01-11       Impact factor: 2.058

2.  Disruption of a Sirt1-dependent autophagy checkpoint in the prostate results in prostatic intraepithelial neoplasia lesion formation.

Authors:  Michael J Powell; Mathew C Casimiro; Carlos Cordon-Cardo; Xiaohong He; Wen-Shuz Yeow; Chenguang Wang; Peter A McCue; Michael W McBurney; Richard G Pestell
Journal:  Cancer Res       Date:  2010-12-28       Impact factor: 12.701

Review 3.  The interaction between HCV and nuclear receptor-mediated pathways.

Authors:  Zoe Raglow; Carly Thoma-Perry; Richard Gilroy; Yu-Jui Yvonne Wan
Journal:  Pharmacol Ther       Date:  2011-05-18       Impact factor: 12.310

Review 4.  Autophagy and endocrine resistance in breast cancer.

Authors:  Katherine L Cook; Ayesha N Shajahan; Robert Clarke
Journal:  Expert Rev Anticancer Ther       Date:  2011-08       Impact factor: 4.512

5.  Molecular mechanisms of neutrophil dysfunction in glycogen storage disease type Ib.

Authors:  Hyun Sik Jun; David A Weinstein; Young Mok Lee; Brian C Mansfield; Janice Y Chou
Journal:  Blood       Date:  2014-02-24       Impact factor: 22.113

6.  Autophagy is involved in adipogenic differentiation by repressesing proteasome-dependent PPARγ2 degradation.

Authors:  Chongben Zhang; Yingke He; Mitsuhara Okutsu; Lai Chun Ong; Yi Jin; Lin Zheng; Pierce Chow; Sidney Yu; Mei Zhang; Zhen Yan
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-06-25       Impact factor: 4.310

7.  Metabolic Reprogramming, Autophagy, and Reactive Oxygen Species Are Necessary for Primordial Germ Cell Reprogramming into Pluripotency.

Authors:  D Sainz de la Maza; A Moratilla; V Aparicio; C Lorca; Y Alcaina; D Martín; M P De Miguel
Journal:  Oxid Med Cell Longev       Date:  2017-07-05       Impact factor: 6.543

8.  ESRRA (estrogen-related receptor α) is a key coordinator of transcriptional and post-translational activation of autophagy to promote innate host defense.

Authors:  Soo Yeon Kim; Chul-Su Yang; Hye-Mi Lee; Jin Kyung Kim; Yi-Sak Kim; Ye-Ram Kim; Jae-Sung Kim; Tae Sung Kim; Jae-Min Yuk; Catherine Rosa Dufour; Sang-Hee Lee; Jin-Man Kim; Hueng-Sik Choi; Vincent Giguère; Eun-Kyeong Jo
Journal:  Autophagy       Date:  2017-09-01       Impact factor: 16.016

9.  15d-prostaglandin J2 protects cortical neurons against oxygen-glucose deprivation/reoxygenation injury: involvement of inhibiting autophagy through upregulation of Bcl-2.

Authors:  Haidong Qin; Weiguo Tan; Zheng Zhang; Lei Bao; Hua Shen; Feng Wang; Feng Xu; Zizheng Wang
Journal:  Cell Mol Neurobiol       Date:  2014-10-28       Impact factor: 5.046

10.  Activating peroxisome proliferator-activated receptor gamma mutant promotes tumor growth in vivo by enhancing angiogenesis.

Authors:  Lifeng Tian; Jie Zhou; Mathew C Casimiro; Bing Liang; John O Ojeifo; Min Wang; Terry Hyslop; Chenguang Wang; Richard G Pestell
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.